A detailed history of Vanguard Group Inc transactions in Omeros Corp stock. As of the latest transaction made, Vanguard Group Inc holds 3,219,118 shares of OMER stock, worth $13.7 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3,219,118
Previous 3,250,284 0.96%
Holding current value
$13.7 Million
Previous $11.2 Million 16.55%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

SELL
$3.04 - $4.23 $94,744 - $131,832
-31,166 Reduced 0.96%
3,219,118 $13.1 Million
Q1 2024

May 10, 2024

BUY
$2.88 - $4.89 $234,282 - $397,791
81,348 Added 2.57%
3,250,284 $11.2 Million
Q4 2023

Feb 14, 2024

BUY
$1.08 - $3.63 $28,171 - $94,688
26,085 Added 0.83%
3,168,936 $10.4 Million
Q3 2023

Nov 14, 2023

BUY
$2.81 - $5.69 $15,570 - $31,528
5,541 Added 0.18%
3,142,851 $9.18 Million
Q2 2023

Aug 14, 2023

BUY
$4.45 - $7.57 $1.41 Million - $2.4 Million
316,579 Added 11.22%
3,137,310 $17.1 Million
Q1 2023

May 15, 2023

BUY
$2.48 - $5.22 $709 - $1,492
286 Added 0.01%
2,820,731 $13.1 Million
Q4 2022

Feb 10, 2023

BUY
$1.75 - $3.96 $2,241 - $5,072
1,281 Added 0.05%
2,820,445 $6.37 Million
Q3 2022

Nov 14, 2022

BUY
$3.09 - $7.46 $289,529 - $698,994
93,699 Added 3.44%
2,819,164 $8.88 Million
Q2 2022

Aug 12, 2022

SELL
$1.92 - $6.28 $1.36 Million - $4.45 Million
-709,232 Reduced 20.65%
2,725,465 $7.5 Million
Q1 2022

May 13, 2022

BUY
$5.07 - $7.2 $389,725 - $553,456
76,869 Added 2.29%
3,434,697 $20.6 Million
Q4 2021

Feb 14, 2022

BUY
$5.67 - $8.54 $409,736 - $617,134
72,264 Added 2.2%
3,357,828 $21.6 Million
Q3 2021

Nov 12, 2021

SELL
$13.4 - $16.3 $805,621 - $979,972
-60,121 Reduced 1.8%
3,285,564 $45.3 Million
Q2 2021

Aug 13, 2021

BUY
$14.81 - $19.13 $49.5 Million - $64 Million
3,345,685 New
3,345,685 $49.6 Million

Others Institutions Holding OMER

About OMEROS CORP


  • Ticker OMER
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 62,730,000
  • Market Cap $267M
  • Description
  • Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers related to dysfunction of the immune system, and addictive and compulsive disorders. The company's clinical program...
More about OMER
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.